Introduction {#S1}
============

Urinary tract infection (UTI) is known to cause significant levels of morbidity and mortality in developed countries and has become a public health concern. *Escherichia coli* is reported to be one of the primary etiologic agents that cause UTI. Emergence of antibiotic resistance in this bacterial pathogen is recognized as one of the greatest threats to global healthcare management system (reviewed in [@B23]).

Multidrug resistant (MDR) isolates causing UTI have serious implications for the empiric therapy against pathogenic isolates and for the possible co-selection of antimicrobial resistant pathogens. There are several factors responsible for dissemination of antimicrobial resistance genes among these pathogens, and plasmid-mediated transfer has been considered one of the most important mechanisms for the horizontal transfer of multidrug resistance ([@B1]). The most widely used plasmid classification scheme is PCR based replicon typing (PBRT) which exploited loci encoding plasmid replication machinery ([@B10], [@B11]) which provided insights into resistance plasmid epidemiology, such as whether resistance dissemination involves diverse plasmids or one dominant "epidemic" type ([@B40]).

A recent review summarized the major plasmid families that are currently emerging in MDR *Enterobacteriaceae* strains isolated in several parts of the world including those conferring resistance to important antibiotics such as extended-spectrum cephalosporins, fluoroquinolones, and aminoglycosides ([@B9]). Certain replicon types were found to be associated with MDR as well as with bacterial disease outbreaks ([@B25]). In turn, this can be useful for epidemiologic surveillance and the development of strategies to prevent their spread ([@B25]; [@B16]). However, evidence of multiple replicon types among individual resistant plasmid questioned the fidelity of the classification technique and demands further characterization of the resistant plasmids to address strategies to prevent their spread.

Conjugation systems play key role for interbacterial transfer of antibiotic resistance genes, pathogenicity, and genes encoding other traits of potential benefit to the bacterial host. The plasmid encoded type IV secretion systems (T4SSs) that belongs to IncP, IncF, and IncI identified in *E. coli* and other species of *Enterobacteriaceae* function exclusively in conjugative DNA transfer and had established its role in organizing bacterial genomes and transmission of antibiotic resistance in clinical settings ([@B12]). In IncI plasmid systems, which have both, type IV pili (T4P) and conjugative pili, the former involved in binding of the donor to the recipient cells and after binding, the F-pilus retracts and a stable association between donor and recipient cells initiated by a process of mating pair stabilization (Mps) that involves the translocation of a structure containing TraG into the recipient cell periplasm which further signals the commencement of conjugative DNA transport and replication by the donor cell ([@B24]). Therefore specific pili types and pili associated proteins were related to the transfer of IncP, IncF and IncI plasmids among this gram-negative organism which was thought to depend on contacts created by these structures at the time of DNA transport ([@B12]).

In this study, we characterized multidrug resistant plasmids obtained from uropathogenic *E. coli* isolates collected from hospitalized patients with respect to β-lactamase and quinolone resistant gene acquisition and their co-transmission by conjugation, a common phenomenon in the natural habitat. Moreover the type of conjugation system followed by the clinical plasmids was explored based on pili and pili associated gene types to understand and evaluate potential of horizontal gene transfer among these gram negative pathogen.

Materials and Methods {#S2}
=====================

Bacterial Culture {#S2.SS1}
-----------------

A total of 80 urine samples were collected from Carmichael Hospital for Tropical Diseases, Kolkata from patients suffering from UTI. *E. coli* were detected in the urine culture positive samples by standard biochemical tests and cultured in Luria Bertani Broth (Hi-Media Laboratories, India). The study protocol was approved by the institutional ethical committee.

Antibiotic Susceptibility Testing {#S2.SS2}
---------------------------------

*Escherichia coli* isolates were tested by Kirby Bauer disk diffusion method on Muller Hinton agar plates using following antibiotic disks; amikacin (AK; 10 μg), ceftazidime (CAZ; 30 μg), cefotaxime (CTX; 30 μg), cefoxitin (CX; 30 μg), ciprofloxacin (CIP; 5 μg), levofloxacin (LE; 5 μg), cotrimoxazole (COT; 25 μg), nitrofurantoin (NIT; 300 μg), and imipenem (IPM; 10 μg) (Hi-Media laboratories, India). *E. coli* ATCC 25922 was used as quality control strain. Isolates resistant, intermediate resistant and sensitive to individual antibiotics were determined by the zone of inhibition that was interpreted following [@B13] guidelines ([@B13]). An isolate was considered as multidrug resistant if it was resistant to ≥3 classes of antibiotics. Extended spectrum β-lactamase production was determined in isolates that were resistant to cephalosporin ([@B36]).

Plasmid Isolation, Bacterial Conjugation, and PCR Analysis {#S2.SS3}
----------------------------------------------------------

Plasmid DNA was prepared by alkaline lysis method and electophoresed on 0.8% agarose gels and visualized by Gel documentation system (BioRad) ([@B27]). Plasmid bands of varied size (approximate) were detected using molecular weight marker, lambda/*Hin*dIII double digest. Conjugal transfer of plasmid to *E. coli* J53AzideR recipient strain was performed by broth mating assay ([@B22]). Transconjugants were screened by double selection method on MacConkey agar plates containing sodium azide (100 μg/ml) and ceftazidime (30 μg/ml), or ciprofloxacin (5 μg/ml), respectively. Plasmids from the clinical isolates and the transconjugants were screened by PCR for the detection of β-lactamase genes; *bla*~TEM~, *bla*~CTX--M~, *bla*~OXA~ ([@B39]; [@B4]) and PMQR genes; *oqxAB, qnrA, qnrB, aac(6′)-Ib-cr, qepA* genes with gene specific primers ([@B39]). Purity of the plasmid preparations isolated from transconjugants was ascertained by PCR with chromosomal gene (*fimH*, *papC*, *cnf1*) specific primers ([Supplementary Table S1](#DS1){ref-type="supplementary-material"}) and RFLP analysis. Discrete difference in the RFLP pattern was observed amongst the plasmid DNA which was absent in genomic DNA isolated from the clinical counterpart that was used as a control ([Supplementary Figures S1](#DS1){ref-type="supplementary-material"}, [S2](#DS1){ref-type="supplementary-material"}, [S3](#DS1){ref-type="supplementary-material"}).

Plasmid Replicon Typing {#S2.SS4}
-----------------------

Incompatibility groups of the plasmids isolated from the transconjugants were determined by PCR-based replicon typing (PBRT) method using IncFrep, F1B, N, I1, A/C, H1, X, Y, L/M, W by specific PCRs as described previously ([@B10]).

*In silico* Analysis {#S2.SS5}
--------------------

An *in silico* analysis was carried out using GenBank BLAST^[1](#footnote1){ref-type="fn"}^ on *E. coli* annotated plasmids of IncF, IncI1, IncN, IncW, IncHI, IncA/C, IncX replicon types. However, due to insufficient data on the various incompatibility types from *E. coli*, the *in silico* analysis was extended to some plasmids of other *Enterobactereace* family. For the seven Inc groups of plasmids incident in this study pili and pili associated genes involved in conjugation event was used as template for nucleotide-Search^[2](#footnote2){ref-type="fn"}^ to identify candidate genes which were specific for individual incompatibility types ([@B5]). The target genes were further validated by blastN (see footnote 2) and ClustalW2 software^[3](#footnote3){ref-type="fn"}^. Primer pairs covering most sequences in each family were designed using FastPCR^[4](#footnote4){ref-type="fn"}^ ([Table 1](#T1){ref-type="table"} and [Supplementary Figure S4](#DS1){ref-type="supplementary-material"}).

###### 

Primers used in this study.

  **Annotated plasmids**   **Primer name**   **Sequence (5′-3′)**      **Length (bp)**   **Amplicon size (bp)**
  ------------------------ ----------------- ------------------------- ----------------- ------------------------
  R100                     *traF*-fp         CCGGCTGCAGAATTACTGGAC     21                114
                           *traF*-rp         CTGCAGTACAGCCATTACAACGG   23                
  R64                      *pilM*-fp         ATGGGATGGCTGGTCATGGCC     21                232
                           *pilM*-rp         CCCTGTCACTCCGGACTCCC      20                
  R46                      *traE*-fp         GCTAATAAAAAAACAGGGC       18                624
                           *traE*-rp         AACCCGGAAGTTAACTGA        18                
  R388                     *trwJ*-fp         TGAAGAAGCTGGTTATGAC       19                560
                           *trwJ*-rp         TATCCAGAACGAAACGAC        18                
  R27                      *trhE*-fp         ATGAAACTTCTCAGCAGGT       19                442
                           *trhE*-rp         AACATCGGTTTTGTTACAAC      20                
  RA1                      *traG*-fp         TTGTTGTTGATGCTCTAAACA     21                350
                           *traG*-rp         ATTGCTTTTATTATCGTGATG     21                
  R6K                      *pilx4*-fp        CGAGTTTTCTCAGATCAGC       19                358
                           *pilx4*-rp        CTAAATCCCTCCTTGCTG        18                

Results {#S3}
=======

Bacterial Isolates {#S3.SS1}
------------------

In the present study 50 urine samples yielded significant growth out of 80 samples collected from patients suffering from UTI. 19 *E. coli* isolates were identified from the 50 urine culture positive samples by routine biochemical analysis.

Antibiotic Resistance {#S3.SS2}
---------------------

All 19 *E. coli* isolates were resistant toward ciprofloxacin, ceftazidime, cefotaxime, cefipime, amikacin, levofloxacin, nitrofurantoin, and imepenem except 2, 3, 4, 8, and 8 out of the 19 which showed intermediate resistance against amikacin, levofloxacin, nitrofurantoin and imepenem, respectively.

Acquired Plasmids and Resistant Gene Profiles {#S3.SS3}
---------------------------------------------

Plasmid profiling of all 19 isolates showed presence of one to seven plasmids of approximate sizes ranging from ∼12 to ∼1 kb. Prevalence of a plasmid of an approximate size in the range of ∼12 kb was common in all isolates. 8 out of 19 isolates exhibited three plasmid bands while one, two, four and five/seven plasmid bands were detected in 2/19, 1/19, 4/19, and 4/19 of the isolates, respectively ([Figure 1](#F1){ref-type="fig"}). Plasmids from all 19 isolates indicated presence of β-lactamase genes *bla*~TEM~, *bla*~CTX--M~, *bla*~OXA~ and the PMQR genes *aac(6')1b-cr*, *oqxAB*, *qnrB* in varied combinations. *bla*~TEM~ and *bla*~OXA~ was observed in all 19 isolates in combination with *bla*~CTX--M--15~ type (13/19), and the PMQR genes; *aac(6′)1b-cr* (14/19), *oqxAB*(2/19), *qnrB*(7/19), and *qnrS* (1/19), respectively ([Table 2](#T2){ref-type="table"}). Therefore it may be assumed that *bla*~TEM~ and *bla*~OXA~ genes harbored by the clinical isolates donot encode ESBLs and exhibited β-lactam- β-lactamase inhibitor resistant phenotype (data not shown).

![Plasmid pattern of clinical uropathogenic *E. coli* isolates. Lanes 1--19, plasmid extracted from the clinical isolates (*n* = 19) and electrophoresed on 0.8% agarose gel. M, lambda/*Hin*dII DNA ladder.](fmicb-10-02913-g001){#F1}

###### 

Resistance genes in the clinical uropathogenic *E. coli* isolates (*n* = 19).

  **Clinical isolates**   **Resistance genes**                            
  ----------------------- ---------------------- ---- ---- ---- ---- ---- ----
  EC175                   \+                     \+   \+   \+   \+   −    −
  EC 176                  \+                     \+   \+   \+   −    −    −
  EC 177                  \+                     −    \+   \+   −    −    −
  EC 178                  \+                     −    \+   \+   −    \+   −
  EC 180                  \+                     \+   \+   −    −    −    \+
  EC183                   \+                     \+   \+   \+   −    −    −
  EC 185                  \+                     \+   \+   \+   −    \+   −
  EC 187                  \+                     −    \+   \+   −    −    −
  EC 194                  \+                     −    \+   \+   −    −    −
  EC 195                  \+                     \+   \+   \+   −    −    −
  EC 197                  \+                     \+   \+   \+   −    −    −
  EC 207                  \+                     \+   \+   \+   \+   \+   −
  EC 211                  \+                     \+   \+   −    −    \+   −
  EC 215                  \+                     \+   \+   −    −    \+   −
  EC 216                  \+                     −    \+   −    −    \+   −
  EC 217                  \+                     \+   \+   −    −    \+   −
  EC 219                  \+                     \+   \+   \+   −    −    −
  EC 222                  \+                     −    \+   \+   −    −    −
  EC 224                  \+                     \+   \+   \+   −    −    −

Conjugal Transfer {#S3.SS4}
-----------------

Transfer of resistance determinants from all 19 clinical *E. coli* donors to the *E. coli* J53AziR recipients strain was observed against β-lactam antibiotics (ceftriazone, ceftazidime, cefotaxime) and fluoroquinolones (ciprofloxacin, levofloxacin). The β-lactamase genes *bla*~TEM~, *bla*~CTX--M~, *bla*~OXA~ and the PMQR genes *aac(6′)1b-cr,oqxAB, qnrB*, respectively were transferred in various combinations ([Table 3](#T3){ref-type="table"}).

###### 

Plasmid replicon types and resistance gene distribution among the transconjugants.

  **Drug selection**   **Transconjugants**   **β-lactamase genes**   **Replicon(s)**   **PMQR genes**                                              
  -------------------- --------------------- ----------------------- ----------------- ---------------- --------------------------- ---- ---- ---- ----
  C                    TCa175                \+                      \+                −                Frep, I1                    \+   \+   −    −
  E                    TCa176                \+                      \+                \+               Frep                        −    −    −    −
  F                    TCa177                \+                      −                 \+               Frep, I1                    \+   −    −    −
  T                    TCa178                \+                      −                 \+               F1B                         −    −    −    −
  A                    TCa180                \+                      \+                \+               F1B                         −    −    −    −
  Z                    TCa183                \+                      \+                \+               Frep,F1B                    \+   −    −    −
  I                    TCa185                \+                      \+                −                Frep, I1                    −    −    −    −
  D                    TCa187                \+                      −                 \+               Frep                        −    −    −    −
  I                    TCa194                \+                      −                 \+               Frep,F1B                    −    −    −    −
  M                    TCa195                \+                      \+                \+               Frep,F1B                    \+   −    −    −
  E                    TCa197                \+                      \+                \+               F1B                         \+   −    −    −
                       TCa207                \+                      \+                \+               Frep                        \+   \+   −    −
                       TCa211                \+                      \+                −                Frep                        \+   −    −    −
                       TCa215                \+                      \+                −                Frep, I1                    \+   −    −    −
                       TCa216                \+                      −                 \+               Frep, I1                    −    −    −    −
                       TCa217                \+                      \+                \+               F1B                         −    −    −    −
                       TCa219                \+                      \+                \+               F1B                         −    −    −    −
                       TCa222                \+                      −                 \+               F1B                         −    −    −    −
                       TCa224                \+                      \+                \+               Frep,N                      \+   −    −    −
  C                    TCi175                \+                      −                 −                Frep,W,X                    \+   −    −    −
  I                    TCi176                \+                      \+                \+               Frep,A/C,F1B,W              \+   −    −    −
  P                    TCi177                \+                      −                 \+               Frep,W                      \+   −    −    −
  R                    TCi178                \+                      −                 −                Frep,I1,L/M,W               \+   −    −    −
  O                    TCi180                \+                      \+                −                Frep,A/C,F1B,Y,W,X          −    −    −    \+
  F                    TCi183                −                       \+                \+               Frep,F1B,W                  \+   −    −    −
  L                    TCi185                \+                      −                 −                Frep                        \+   −    \+   −
  O                    TCi187                \+                      −                 −                Frep,I1                     \+   −    −    −
  X                    TCi194                \+                      −                 \+               Frep,F1B                    \+   −    −    −
  A                    TCi195                \+                      −                 \+               Frep                        \+   −    −    −
  C                    TCi197                \+                      \+                \+               Frep                        \+   −    −    −
  I                    TCi207                \+                      −                 −                Frep,FIB,W                  \+   −    \+   −
  N                    TCi211                \+                      \+                \+               Frep,A/C,F1B,W              −    −    \+   −
                       TCi215                \+                      −                 \+               Frep,F1B,W                  −    −    \+   −
                       TCi216                \+                      −                 \+               Frep,L/M,W,X                −    −    \+   −
                       TCi217                                        \+                \+               Frep                        −    −    \+   −
                       TCi219                \+                      −                 \+               Frep,F1B,W,X                \+   −    −    −
                       TCi222                \+                      −                 −                Frep,A/C,F1B, F11S,H1,W,X   \+   −    −    −
                       TCi224                \+                      −                 \+               I1,W                        \+   −    −    −

Selection of transconjugants against ceftazidime and ciprofloxacin independently showed acquisition of resistant plasmids with both single as well as multiple replicon types with universal presence of IncF type plasmid. Single replicon type plasmid which belonged to IncF type (IncFrep) was observed in four transconjugants selected against ciprofloxacin and 10 (IncFIB; 6, IncFrep; 4) selected against ceftazidime respectively. Additionally presence of multiple replicon Inc type plasmids (I1, W, X, Y, A/C, L/M, HI) were detected in transconjugants obtained under ciprofloxacin compared to IncF and IncI1 obtained under ceftazidime selection ([Table 3](#T3){ref-type="table"}).

Identification of Pili and Pili Associated Genes {#S3.SS5}
------------------------------------------------

Genes encoding pili and pili associated proteins were members of the bacterial T4SS system and actively participates facilitating the IncF and IncP bacterial conjugation machinery. However, pili associated with IncI conjugation system enhances the process of conjugation without directly playing a role in the transfer mechanism. Nucleotide sequences of genes encoding pili and pili associated proteins were identified in the annotated plasmids R100 (Ac No. NC_002134.1), R64 (Ac.No. AP005147.1.), R46 (Ac.No NC_003292.1.), R388 (Ac.No. NC_028464.1), R27 (Ac.No NC_002305.1), pRA1 (Ac.No NC_012885.1), R6K (Ac No AJ006342.1) assigned to IncF, IncI, IncN, IncW IncH, IncA/C, and IncX plasmid incompatibility types, respectively ([Table 4](#T4){ref-type="table"}) to characterize the conjugation system type in the transconjugants that harbor plasmid of multiple replicon types.

###### 

Pili and pili associated genes in annotated plasmids assigned to specific plasmid replicon types.

  **Replicon**   **Annotated**   **Accession No.**            **Genes encoding**   
  -------------- --------------- ---------------------------- -------------------- --------
  IncF           R100            [NC_002134.1](NC_002134.1)                        *traF*
  IncI1          R64             [AP005147.1](AP005147.1)     *pilM*               
  IncN           R46             [NC_003292.1](NC_003292.1)                        *traE*
  IncW           R388            [NC_028464.1](NC_028464.1)                        *trwJ*
  IncH           R27             [NC_002305.1](NC_002305.1)                        *trhE*
  IncA/C         pRA1            [NC_012885.1](NC_012885.1)                        *traG*
  IncX           R6K             [AJ006342.1](AJ006342.1)     *pilx4*              

Plasmid isolated from the 16 and 3 transconjugants obtained under ceftazidime selection showed presence of *tra*F and *pil*M, respectively ([Table 5](#T5){ref-type="table"}). Overall similar results were observed in transconjugants selected under ciprofloxacin pressure, however, the transconjugants that exhibited presence of *pil*M amongst the later group were *tra*F positive amongst the former respectively ([Table 5](#T5){ref-type="table"}). Moreover combination of *tra*F and *pil*M or other pili associated genes *trw*J, *tra*E, *trh*E, *tra*E, and *pil*x4 were not detected. Presence of *tra*F and *pil*M amongst the transconjugants were further confirmed by southern blot hybridization using the *traF* and *pilM* cloned amplicons as probes (data not shown).

###### 

Conjugal plasmid types associated with transmissible resistant plasmids in transconjugants.

  **Drug selection**   **Transconjugants**   **Pili and pili associated genes**   **Conjugal plasmid types**                       
  -------------------- --------------------- ------------------------------------ ---------------------------- --- --- --- --- --- ---
  C                    TCa175                \+                                   −                            −   −   −   −   −   F
  E                    TCa176                \+                                   −                            −   −   −   −   −   F
  F                    TCa177                −                                    \+                           −   −   −   −   −   I
  T                    TCa178                \+                                   −                            −   −   −   −   −   F
  A                    TCa180                \+                                   −                            −   −   −   −   −   F
  Z                    TCa183                \+                                   −                            −   −   −   −   −   F
  I                    TCa185                \+                                   −                            −   −   −   −   −   F
  D                    TCa187                \+                                   −                            −   −   −   −   −   F
  I                    TCa194                \+                                   −                            −   −   −   −   −   F
  M                    TCa195                \+                                   −                            −   −   −   −   −   F
  E                    TCa197                \+                                   −                            −   −   −   −   −   F
                       TCa207                \+                                   −                            −   −   −   −   −   F
                       TCa211                \+                                   −                            −   −   −   −   −   F
                       TCa215                −                                    \+                           −   −   −   −   −   I
                       TCa216                −                                    \+                           −   −   −   −   −   I
                       TCa217                \+                                   −                            −   −   −   −   −   F
                       TCa219                \+                                   −                            −   −   −   −   −   F
                       TCa222                \+                                   −                            −   −   −   −   −   F
                       TCa224                \+                                   −                            −   −   −   −   −   F
  C                    TCi175                \+                                   −                            −   −   −   −   −   F
  I                    TCi 76                \+                                   −                            −   −   −   −   −   F
  P                    TCi177                \+                                   −                            −   −   −   −   −   F
  R                    TCi178                −                                    \+                           −   −   −   −   −   I
  O                    TCi 80                \+                                   −                            −   −   −   −   −   F
  F                    TCi183                \+                                   −                            −   −   −   −   −   F
  L                    TCi185                \+                                   −                            −   −   −   −   −   F
  O                    TCi187                −                                    \+                           −   −   −   −   −   I
  X                    TCi194                \+                                   −                            −   −   −   −   −   F
  A                    TCi195                \+                                   −                            −   −   −   −   −   F
  C                    TCi197                \+                                   −                            −   −   −   −   −   F
  I                    TCi207                \+                                   −                            −   −   −   −   −   F
  N                    TCi211                \+                                   −                            −   −   −   −   −   F
                       TC i215               \+                                   −                            −   −   −   −   −   F
                       TCi 216               \+                                   −                            −   −   −   −   −   F
                       TCi217                \+                                   −                            −   −   −   −   −   F
                       TCi219                \+                                   −                            −   −   −   −   −   F
                       TCi222                \+                                   −                            −   −   −   −   −   F
                       TCi224                −                                    \+                           −   −   −   −   −   I

Discussion {#S4}
==========

In this study, we focused on the genetic classification of the transmissible plasmids isolated from multidrug resistant uropathogenic *E. coli* which has an impact on dissemination of drug resistance amongst this uropathogen. Multidrug resistance is an emerging threat propagated in this pathogenic microbe. Worldwide and nationwide studies showed different resistance rates against several antibiotic groups (reviewed in [@B23]). Moreover recent reports from India indicated an alarming rise in the incidence of multidrug resistance (i.e., simultaneous resistance to various class of antibiotics, such as aminoglycosides, cephalosporins fluoroquinolones) amongst the uropathogenic *E. coli* isolates that varied from 76.51 to 100 ([@B2]; [@B31]; [@B32]) that was very similar to our study which cause difficulty in clinical management especially in a resource poor country, India.

It is of particular concern that resistance to β-lactams and fluoroquinolones is frequently driven by plasmid-borne extended spectrum β-lacatmase genes and plasmid mediated quinolone resistance (PMQR) genes in this uropathogen ([@B39]). Various reports suggested acquisition of plasmids of varied size and numbers associated with multiple drug resistant genes among pathogenic *E. coli* worldwide and nationwide ([@B35]; [@B27]) with incidence of a plasmid band at 26 or 21 kb, respectively ([@B26]; [@B27]). In this study the number and size of the clinical plasmids varied with predominance of a ∼12 kb band. Incidence of two or more plasmid borne β-lactamase (*bla*~TEM~, *bla*~CTX--M~, *bla*~OXA~) and either one or two PMQR (*aac-1b-cr*, *oqxAB*, *qnrB*, *qnrS*) genes was observed. The resistant genes were successfully transmitted by conjugation in an environment irrespective of ceftazidme/ciprofloxacin selection. Successive co-existence and co-transmission ([@B17]) of these resistant determinants were previously reported that poses difficulty in health care management. Random administration of the respective group of drugs facilitates mobilization of plasmids that carry resistance genes by horizontal gene transfer (HGT) through natural mechanisms such as conjugation or transformation ([@B15]). Additionally resistant plasmids confer positively selectable phenotypes with the presence of antimicrobial resistance genes. Other essential regions of plasmid include their replication origin involved in replication and genes that are involved in the formation of *trans*-envelope machinery and pili structure that includes Type IV secretion system (T4SS), a large macromolecular machinery which control conjugation and dissemination of antibiotic resistance ([@B20]; [@B8]). T4SSs are implicated not only in bacterial conjugation but also in the secretion of virulence factors to the host. IncF, IncP, and IncI conjugation systems were reported in *E. coli* that were further related to plasmid incompatibility groups ([@B24]) which were ascertained to understand resistance plasmid epidemiology, as well as strain epidemiology ([@B19]). Additionally the T4SSs encoded in plasmids with IncI conjugation system have a number of physical and functional features that distinctly distinguish them from the IncF and IncP systems in the *Enterobacteriaceae* strains ([@B24]).

In this study predominance of multiple replicon types were observed among individual plasmid screened from the transconjugants irrespective of ceftazidime/ciprofloxacin selection although the number increased in the latter. Acquisition of resistant plasmid with multiple replicon types were reported ([@B25]) that may be attributed to frequent recombination events under antibiotic selection which creates difficulty in typing the resistant plasmids and their mode of dissemination. The random recombination events may also result in re-shuffling of resistant genes under antibiotic pressure during selection of transconjugants. However, conjugative-plasmid transfer in the gram-negative bacteria was observed to be related to contacts created by the conjugative pilus machinery which was constitutively expressed and independent of antibiotic selection ([@B30]). Pili and pili associated gene types assisting in conjugal transfer of resistant plasmids were thought to be universally present amongst these plasmids that disseminated by IncF, IncP, and IncI conjugation system, respectively. A variety of mechanisms and structures involved in the transport of DNA amongst bacteria was dependent on the assembly of a pilus, be it an F, P, I, or T pilus, which brings cells together and provides an interface to exchange macromolecules directly from cell to cell ([@B24]; [@B38]).

Nucleotide sequences of genes encoding pili and pili associated genes identified from annotated plasmids R100, R64, R46, R388, R27, RA1, R6K assigned to IncF, IncI, IncN, IncW IncH, IncA/C, and IncX plasmid replicon types, respectively ([@B6]; [@B11]) revealed patterns of association that corresponds to those of the constituent single family replicons like IncF types (IncFrep, IncF1B, IncF11S), IncI, IncN, IncW, IncH, IncA/C, IncX associated with *traF* ([@B3]), *pilM* ([@B28]), *traE* ([@B18]), *trwJ* ([@B29]; [@B41]; [@B33]), *trhA* ([@B34]; [@B37]), *traG* ([@B21]), and *pilX4* ([@B6]) genes related to the conjugation system types respectively. In this study absence of *traE*, *trwJ*, *trhA*, *traG*, *pilx4* and presence of *traF* and *pilM* types among the resistant transmissible plasmids selected individually against ceftazidime and ciprofloxacin from all 19 transconjugants indicated that either IncF or IncI conjugation system was involved in the dissemination of the resistant determinants respectively. Conjugation system followed during the transfer of individual plasmid with multiple replicon type to the recipient strain was identical (F-type) in 13 out of 19 of the donor strains irrespective of the drug selection pressure. Moreover variation in the type of conjugation system (IncF/IncI) with respect to drug selection was observed in six clinical donors during conjugal transfer of genetic material to the recipient strain. Hence our study indicated that plasmid isolated from MDR uropathogenic *E. coli* obtained from hospitalized patients from the eastern part of India showed successful transmissibility by IncF and IncI conjugation system, the former being predominant. As bacteria have developed sophisticated ways to select, attach and infect their target cells, so adhesive and secretion pili serves as key protagonists during these events ([@B14]; [@B7]; [@B24]). Therefore pili and pili associated genes in transmissible resistance gene-carrying plasmids irrespective of their incompatibility types drives the success of recipient strains toward dissemination of drug resistance. Furthermore the results of this study also indicated that the type of conjugation system was independent of the associated resistance genes and the drugs used for selection that implied acquisition of resistance genes to be random, however, their dissemination was dependent upon the pili type related to T4SS of the transmissible plasmid that harbored the resistant determinants. Therefore the strength of this study relies on introduction of a novel technique of bio-typing plasmids of multiple replicon types in uropathogenic *E. coli* isolated from clinical settings. However, there were limitations as this study was conducted on a small pool of uropathogenic *E. coli* isolates. Moreover the conjugation system of plasmids without Inc group (non-typeable) could not be addressed by this technique due to their absence in the limited pool of isolates investigated.

Conclusion {#S5}
==========

In summary, this is the first study of its kind which addressed novel technique of bio-typing plasmids of multiple replicon types in uropathogenic *E. coli* based on pili and pili associated genes. These plasmids were multidrug resistant and transmissible by conjugation, although the dissemination was independent of the associated resistance genes.
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